Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
To enhance the accuracy of SEs in eliminating cancer cells
2024-04-26

To enhance the accuracy of SEs in eliminating cancer cells, the mAb recognized by specific arn-509 on tumor cells were fused with SEs. Fab C215 or C242 fused with SEA promoted apoptosis in human colon carcinoma cells via Fas (Dohlsten et al., 1994, Litton et al., 1996). SEB-incorporated exosomes wer
-
Despite the absence of disulfide
2024-04-26

Despite the absence of disulfide bonds in its linear structure, KT43C displays antifungal and antibacterial activity. Disulfide bonds are determinants of defensins' integrity and have been reported to increase the antimicrobial activity (Jenssen et al., 2006). However, some linear derivatives of AMP
-
No starting dose adjustment is needed
2024-04-26

No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad
-
From a clinical utility standpoint this study showed
2024-04-26

From a clinical utility standpoint, this study showed that AR can be useful in the GATA3-positive tumor of unknown origin setting. Epidemiologically, in this setting, the top 2 diagnoses in the differential diagnosis are metastatic carcinoma of breast origin or urothelial origin [18]. Seven out of 1
-
GSK180 Based on their different sources the
2024-04-25

Based on their different sources, the APN inhibitors (APNIs) can be divided into the natural products and synthetic compounds. Bestatin (1, Fig. 1), isolated from the Streptomyces oliuoreticuli by Umezawa et al., is the first reported and only marketed natural dipeptidomimetic inhibitor of APN. Afte
-
The rescue of the behavioral deficit was associated
2024-04-25

The rescue of the behavioral deficit was associated with a significant reduction in the levels of both soluble and insoluble Aβ peptides and their deposition in the Fluconazole of the same animals. In search for the mechanism behind the reduced amyloidosis, we assessed APP metabolism. Confirming pre
-
It is noteworthy to mention the limitations of this study
2024-04-25

It is noteworthy to mention the limitations of this study like tPA plus LB1 treatment beyond 4 h after stroke was not investigated. Especially 6 or 8 h after stroke could be studied in future projects for translational purposes. Second drawback might be that we performed the experiments in different
-
br Conclusion P gingivalis expresses various exopeptidases i
2024-04-25

Conclusion P. gingivalis expresses various exopeptidases, i.e., DPP4, DPP5, DPP7, DPP11, PtpA, and AOP, in periplasmic space, which produce di- and tri-peptides from most oligopeptides. This oligopeptide processing step is important as an extracellular event in the Pioglitazone of asaccharolytic
-
When a clinician diagnoses a
2024-04-25

When a clinician diagnoses a person with AD, the person is transformed into a patient with the disease. The person is a member of a patient group associated with behaviors, abilities, and experiences related both formally and informally to the diagnosis [10]. The diagnostic label implies what signs
-
br Acknowledgements Dr Paul J Gasser is supported by the
2024-04-25

Acknowledgements Dr. Paul J. Gasser is supported by the National Institutes of Health (grant number R01DA032895), and the Charles E. Kubly Mental Health Research Center. Dr. Christopher A. Lowry is supported by the National Institutes of Health (grant number R21 MH116263), the Department of the N
-
An alternative approach to the administration of ADO agonist
2024-04-25

An alternative approach to the administration of ADO agonists is to amplify the actions of endogenous ADO by inhibiting the ADO-metabolizing enzyme, ADO kinase (AK). Inhibition of AK has the net effect of potentiating the local concentration and the effects of ADO in the extracellular compartment. T
-
Furthermore our lab previously reported that cadmium treatme
2024-04-25

Furthermore, our lab previously reported that cadmium treatment increased AChE-S and decreased AChE-R variants gene expression, which mediates the cell death observed on basal forebrain cholinergic neurons (Del Pino et al., 2016b). AChE-R decreased expression, which presents a neuroprotective role i
-
At present drugs that specifically inhibit YAP activity are
2024-04-25

At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi
-
The take home message here
2024-04-25

The take-home message here is that, although Aurora A phosphorylated on T288 is the activated isoform of Aurora A, measuring the level of phosphorylation of T288 does not reflect Aurora A kinase activity (Figure 5). What would be the most appropriate readout for an in vivo Aurora A kinase activity
-
This evidence suggests the strong clinical relevance
2024-04-24

This evidence suggests the strong clinical relevance of the identification of acquired resistance mechanisms for a proper therapeutic decision in patients with ALK-rearranged NSCLC. When the tissue is not available, the analysis of circulating tumor DNA (cfDNA) can be a valid alternative for the det
15875 records 186/1059 page Previous Next First page 上5页 186187188189190 下5页 Last page